X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4178) 4178
Publication (182) 182
Newsletter (18) 18
Book Review (16) 16
Magazine Article (11) 11
Book Chapter (8) 8
Dissertation (4) 4
Conference Proceeding (3) 3
Data Set (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3604) 3604
male (2040) 2040
female (2013) 2013
daunorubicin - therapeutic use (1741) 1741
antineoplastic combined chemotherapy protocols - therapeutic use (1734) 1734
daunorubicin - administration & dosage (1704) 1704
adult (1562) 1562
middle aged (1465) 1465
cytarabine - administration & dosage (1246) 1246
adolescent (1168) 1168
leukemia, myeloid, acute - drug therapy (1145) 1145
aged (1003) 1003
oncology (957) 957
hematology (890) 890
child (859) 859
remission induction (812) 812
daunorubicin (757) 757
cytarabine - therapeutic use (725) 725
animals (706) 706
index medicus (690) 690
chemotherapy (609) 609
child, preschool (586) 586
vincristine - administration & dosage (524) 524
treatment outcome (503) 503
prognosis (502) 502
acute disease (501) 501
vincristine - therapeutic use (499) 499
daunorubicin - adverse effects (477) 477
antineoplastic agents - therapeutic use (449) 449
cancer (445) 445
mice (442) 442
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (388) 388
antineoplastic combined chemotherapy protocols - adverse effects (386) 386
daunorubicin - analogs & derivatives (381) 381
leukemia - drug therapy (369) 369
infant (368) 368
drug therapy, combination (349) 349
prednisone - therapeutic use (341) 341
doxorubicin - therapeutic use (336) 336
time factors (331) 331
leukemia, myeloid - drug therapy (326) 326
antibiotics, antineoplastic - therapeutic use (324) 324
prednisone - administration & dosage (314) 314
leukemia, lymphoid - drug therapy (313) 313
leukemia (309) 309
leukemia, myeloid, acute - mortality (305) 305
acute myelogenous leukemia (304) 304
cyclophosphamide - administration & dosage (298) 298
methotrexate - administration & dosage (298) 298
daunorubicin - pharmacology (294) 294
etoposide - administration & dosage (292) 292
disease-free survival (291) 291
combined modality therapy (284) 284
therapy (280) 280
thioguanine - administration & dosage (280) 280
acute myeloid leukemia (265) 265
pharmacology & pharmacy (265) 265
methotrexate - therapeutic use (264) 264
asparaginase - administration & dosage (263) 263
survival rate (262) 262
cyclophosphamide - therapeutic use (257) 257
mercaptopurine - administration & dosage (256) 256
follow-up studies (248) 248
remission, spontaneous (245) 245
drug administration schedule (242) 242
asparaginase - therapeutic use (239) 239
acute myeloid-leukemia (238) 238
doxorubicin (236) 236
recurrence (227) 227
survival analysis (226) 226
prednisolone - administration & dosage (225) 225
drug resistance (222) 222
dose-response relationship, drug (220) 220
cytarabine - adverse effects (218) 218
doxorubicin - administration & dosage (214) 214
anthracyclines (209) 209
mercaptopurine - therapeutic use (207) 207
cytarabine (204) 204
leukemia, myeloid, acute - pathology (197) 197
antineoplastic combined chemotherapy protocols - administration & dosage (196) 196
idarubicin (195) 195
aged, 80 and over (194) 194
clinical trials as topic (193) 193
thioguanine - therapeutic use (190) 190
drug evaluation (188) 188
mitoxantrone - administration & dosage (187) 187
neoplasms - drug therapy (182) 182
retrospective studies (180) 180
age factors (177) 177
bone marrow transplantation (174) 174
apoptosis (171) 171
antibiotics, antineoplastic - administration & dosage (169) 169
bone marrow - pathology (165) 165
pediatrics (165) 165
idarubicin - administration & dosage (163) 163
leukemia, myeloid, acute - therapy (162) 162
cell line, tumor (152) 152
prospective studies (152) 152
aml (150) 150
children (150) 150
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3486) 3486
Japanese (159) 159
German (124) 124
Russian (114) 114
French (90) 90
Italian (79) 79
Spanish (47) 47
Polish (42) 42
Chinese (32) 32
Czech (11) 11
Danish (6) 6
Hungarian (4) 4
Dutch (3) 3
Serbian (3) 3
Bulgarian (2) 2
Croatian (2) 2
Portuguese (2) 2
Swedish (2) 2
Bosnian (1) 1
Hebrew (1) 1
Korean (1) 1
Norwegian (1) 1
Persian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the National Cancer Institute, ISSN 0027-8874, 1/2010, Volume 102, Issue 1, pp. 14 - 25
Due to the aging of the populations of developed countries and a common occurrence of risk factors, it is increasingly probable that a patient may have both... 
DOXORUBICIN-INDUCED CARDIOTOXICITY | TRASTUZUMAB-RELATED CARDIOTOXICITY | ONCOLOGY | SPORADIC COLORECTAL ADENOMAS | VASCULAR-DISRUPTING AGENTS | TYROSINE KINASE INHIBITOR | N-ACETYLCYSTEINE | DAUNORUBICIN-INDUCED CYTOTOXICITY | HIGH-DOSE CHEMOTHERAPY | EARLY BREAST-CANCER | ATRIAL-FIBRILLATION | Atrial Fibrillation - chemically induced | Cardiovascular Diseases - prevention & control | Humans | Patient Care Team | Atrial Fibrillation - physiopathology | Ventricular Dysfunction, Left - chemically induced | Flavonoids - therapeutic use | Cardiotonic Agents - therapeutic use | Venous Thromboembolism - prevention & control | Cardiovascular System - physiopathology | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Antineoplastic Agents - adverse effects | Hypertension - chemically induced | Hypertension - prevention & control | Polyphenols | Free Radical Scavengers - therapeutic use | Acetylcysteine - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Cardiovascular Diseases - diagnosis | Heart - physiopathology | Cardiovascular Diseases - physiopathology | Stroke Volume - drug effects | Anticoagulants - therapeutic use | Cardiovascular System - drug effects | Hypertension - physiopathology | Ventricular Dysfunction, Left - physiopathology | Ventricular Dysfunction, Left - prevention & control | Cardiovascular Diseases - microbiology | Animals | Blood Coagulation - drug effects | Venous Thromboembolism - physiopathology | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Phenols - therapeutic use | Venous Thromboembolism - chemically induced | Heart - drug effects | Cardiovascular Diseases - chemically induced | Atrial Fibrillation - prevention & control | Antimitotic agents | Complications and side effects | Aging | Physiological aspects | Dosage and administration | Research | Cardiovascular diseases | Antineoplastic agents | Risk factors | Index Medicus | Review
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1691 - 1699
Summary Background Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the... 
Hematology, Oncology and Palliative Medicine | AML | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | BONE-MARROW | CLASSIFICATION | FLT3 MUTATIONS | CYTARABINE | STEM-CELL TRANSPLANTATION | COMBINATION | ELDERLY-PATIENTS | CHEMOTHERAPY | Niacinamide - analogs & derivatives | Recurrence | Age Factors | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Transplantation, Homologous | Neoadjuvant Therapy - mortality | Time Factors | Phenylurea Compounds - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Chemotherapy, Adjuvant | Daunorubicin - therapeutic use | Double-Blind Method | Risk Factors | Kaplan-Meier Estimate | Niacinamide - adverse effects | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Leukemia, Myeloid, Acute - diagnosis | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Germany | Antimitotic agents | Clinical trials | Chemotherapy | Antineoplastic agents | Standards | Cancer
Journal Article
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 21, pp. 3239 - 3246
Journal Article
Blood, ISSN 0006-4971, 12/2017, Volume 130, Issue 23, pp. 2469 - 2474
In 2017, 4 drugs received US Food and Drug Administration marketing approval for acute myeloid leukemia (AML) treatment: targeted therapies for mutant FLT3 and... 
ADULT PATIENTS | TREATMENT-NAIVE | OLDER PATIENTS | INDUCTION CHEMOTHERAPY | LOW-DOSE CYTARABINE | OPEN-LABEL | ACUTE MYELOID-LEUKEMIA | TRANS-RETINOIC ACID | KINASE INHIBITOR | GREATER-THAN-OR-EQUAL-TO-65 YEARS | HEMATOLOGY | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Triazines - therapeutic use | Humans | Leukemia, Myeloid, Acute - metabolism | Staurosporine - analogs & derivatives | Isocitrate Dehydrogenase - antagonists & inhibitors | Molecular Targeted Therapy | fms-Like Tyrosine Kinase 3 - genetics | Aminopyridines - therapeutic use | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Antibodies, Monoclonal, Humanized - pharmacology | Leukemia, Myeloid, Acute - drug therapy | Daunorubicin - administration & dosage | Triazines - pharmacology | Antibodies, Monoclonal, Humanized - therapeutic use | Isocitrate Dehydrogenase - genetics | Treatment Outcome | Clinical Trials as Topic | Sulfonamides - pharmacology | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Sulfonamides - therapeutic use | Staurosporine - therapeutic use | Aminopyridines - pharmacology | Sialic Acid Binding Ig-like Lectin 3 - antagonists & inhibitors | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Liposomes | Mutation | Aminoglycosides - pharmacology | Staurosporine - pharmacology | Aminoglycosides - therapeutic use | Leukemia, Myeloid, Acute - genetics
Journal Article
Journal Article
by Vellenga, Edo and van Putten, Wim and Ossenkoppele, Gert J and Verdonck, Leo F and Theobald, Matthias and Cornelissen, Jan J and Huijgens, Peter C and Maertens, Johan and Gratwohl, Alois and Schaafsma, Ron and Schanz, Urs and Graux, Carlos and Schouten, Harry C and Ferrant, Augustin and Bargetzi, Mario and Fey, Martin F and Löwenberg, Bob and Ferrant, A and Delannoy, A and Maertens, J and Verhoef, G and Bosly, A and Graux, C and Breems, D. A and Zachee, P and Mineur, P and Jaeger, E and Theobald, M and Beck, J and Fischer, Th and Bargetzi, M and Wernli, M and Gratwohl, A and Fey, M. F and Pabst, T and Chapuis, B and Chalandon, Y and Herr, A and Wuillemin, W. A and Gregor, M and Jacky, E and Schanz, U and Leoncini-Francini, L and Marini, G and Piquet, D and Zimmerli-Schwab, B and Hess, U and Binder, D and Kroner, Th and Wittebol, S and van der Lelie, J and Biemond, B. J and Leeksma, O. C and Ossenkoppele, G. J and Huijgens, P. C and Soesan, M and Wijermans, P. W and Schaafsma, M. R and Legdeur, M and Vellenga, E and Daenen, S. M. G. J and Voogt, P. J and Schouten, H. C and Biesma, D. H and de Weerdt, O and Löwenberg, B and Cornelissen, J. J and Sonneveld, P and Zijlmans, J and Jongen-Lavrencic, M and de Greef, G. E and Verdonck, L. F and Kuball, J and van Marwijk Kooy, M and Dutch-Belgian Hematooncology Coope and Swiss Grp Clinical Canc Res Collab and Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research Collaborative Group (SAKK) and for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), and Swiss Group for Clinical Cancer Research Collaborative Group (SAKK)
Blood, ISSN 0006-4971, 2011, Volume 118, Issue 23, pp. 6037 - 6042
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2012, Volume 30, Issue 32, pp. 3924 - 3931
Journal Article